Search research articles
Contact Us
Filters
Showing results (41-50 of 81) with videos related to
Page
of 9
Sort By:
International Journal of Methods in Psychiatric Research
|
August 26, 2020
Evaluating functional disability in clinical trials of lisdexamfetamine dimesylate in binge eating disorder using the Sheehan Disability Scale
Karen S Yee, Robin Pokrzywinski, Asha Hareendran, et al.
Journal of Psychiatric Research
|
August 23, 2002
Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR
Stuart A Montgomery, David V Sheehan, Paolo Meoni, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
August 21, 2012
Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States
Anthony J Rothschild, Atul R Mahableshwarkar, Paula Jacobsen, et al.
International Clinical Psychopharmacology
|
November 25, 2010
Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale
David V Sheehan, Kathy Harnett-Sheehan, Melissa E Spann, et al.
International Clinical Psychopharmacology
|
September 8, 2012
Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies
Michele Mancini, David V Sheehan, Koen Demyttenaere, et al.
Depression and Anxiety
|
November 5, 2002
Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine
R Douglas Shytle, Archie A Silver, Kathy H Sheehan, et al.
Psychiatry Research
|
March 30, 2007
Perceived stress in anxiety disorders and the general population: a study of the Sheehan stress vulnerability scale
Kathryn M Connor, Sandeep Vaishnavi, Jonathan R T Davidson, et al.
The Journal of Clinical Psychiatry
|
May 28, 2016
Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Trial
Suresh Durgam, Carl Gommoll, Giovanna Forero, et al.
Innovations in Clinical Neuroscience
|
July 18, 2018
Effects of Lisdexamfetamine Dimesylate on Functional Impairment Measured on the Sheehan Disability Scale in Adults With Moderate-to-severe Binge Eating Disorder: Results from Two Randomized, Placebo-controlled Trials
David V Sheehan, Maria Gasior, Susan L McElroy, et al.
Journal of Clinical Psychopharmacology
|
November 1, 2013
A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder
Angelo Sambunaris, Anjana Bose, Carl P Gommoll, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 81) with videos related to
Sort By:
Page
of 9
International Journal of Methods in Psychiatric Research
|
August 26, 2020
Evaluating functional disability in clinical trials of lisdexamfetamine dimesylate in binge eating disorder using the Sheehan Disability Scale
Karen S Yee, Robin Pokrzywinski, Asha Hareendran, et al.
Journal of Psychiatric Research
|
August 23, 2002
Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR
Stuart A Montgomery, David V Sheehan, Paolo Meoni, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
August 21, 2012
Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States
Anthony J Rothschild, Atul R Mahableshwarkar, Paula Jacobsen, et al.
International Clinical Psychopharmacology
|
November 25, 2010
Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale
David V Sheehan, Kathy Harnett-Sheehan, Melissa E Spann, et al.
International Clinical Psychopharmacology
|
September 8, 2012
Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies
Michele Mancini, David V Sheehan, Koen Demyttenaere, et al.
Depression and Anxiety
|
November 5, 2002
Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine
R Douglas Shytle, Archie A Silver, Kathy H Sheehan, et al.
Psychiatry Research
|
March 30, 2007
Perceived stress in anxiety disorders and the general population: a study of the Sheehan stress vulnerability scale
Kathryn M Connor, Sandeep Vaishnavi, Jonathan R T Davidson, et al.
The Journal of Clinical Psychiatry
|
May 28, 2016
Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Trial
Suresh Durgam, Carl Gommoll, Giovanna Forero, et al.
Innovations in Clinical Neuroscience
|
July 18, 2018
Effects of Lisdexamfetamine Dimesylate on Functional Impairment Measured on the Sheehan Disability Scale in Adults With Moderate-to-severe Binge Eating Disorder: Results from Two Randomized, Placebo-controlled Trials
David V Sheehan, Maria Gasior, Susan L McElroy, et al.
Journal of Clinical Psychopharmacology
|
November 1, 2013
A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder
Angelo Sambunaris, Anjana Bose, Carl P Gommoll, et al.
Page
of 9